IQVIA Biotech was approached by a clinical-stage biopharmaceutical company to run its Phase II prostate cancer drug trial in the U.S. For the Phase II trial, the sponsor was searching for a CRO with an oncology-dedicated group, specific prostate cancer expertise, an ability to be flexible in implementation, and a willingness to provide transparency in the trial’s execution.